Léčba hepatitidy C přímo působícími virostatiky

Title in English Therapy of chronic hepatitis C using direct-acting antivirals
Authors

HUSA Petr

Year of publication 2022
Type Article in Periodical
Magazine / Source Farmakoterapeutická revue
MU Faculty or unit

Faculty of Medicine

Citation
Web https://farmakoterapeutickarevue.cz/cs/lecba-hepatitidy-c-primo-pusobicimi-virostatiky
Keywords viral hepatitis C; Directly Acting Antivirals (DAA); interferon-free therapy
Description Hepatitis C virus (HCV) infection is still a major cause of chronic liver diseases, with approximately 71 million chronically infected persons worldwide. People who inject drugs currently or in the past (PWID), mostly intravenously, are the main risk group among HCV chronically infected persons. The efficacy of therapy with direct-acting antivirals (DAA) is almost 100 %. Currently, the main mission is to diagnose and treat HCV infection in the most possible number of infected persons; it is in collision with poor adherence of PWID in particular.

You are running an old browser version. We recommend updating your browser to its latest version.

More info